JAMES MCLAUGHLIN cut his teeth building life science companies as a venture associate with Third Rock Ventures. But it was an interest in ophthalmology earlier in his career that sparked McLaughlin to start and lead his own company. Gemini Therapeutics is tackling the “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss. While at Third Rock, McLaughlin helped create Voyager Therapeutics, where he headed up operations. McLaughlin, now 34, co-founded Gemini in 2015 to develop therapies that target genetically defined subgroups of AMD patients.
James McLaughlin, Gemini Therapeutics • Photography by David Fox Photographer